MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
MBX Biosciences, Inc. (MBX)
Company Research
Source: GlobeNewswire
CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company’s Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies. “I am thrilled to welcome Steve Hoerter to the Company’s Board as an independent director,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “As a seasoned leader within the biopharmaceutical industry, Steve has scaled multiple biotech companies into revenue-generating commercial enterprises. We look forward to benefiting from his contributions as we advance MBX Biosciences’ growing pipeline of pr
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences (NASDAQ:MBX) was given a new $50.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.MarketBeat
- MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13GlobeNewswire
- MBX Biosciences (NASDAQ:MBX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MBX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains [Seeking Alpha]Seeking Alpha
- MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong sell" rating.MarketBeat
MBX
Earnings
- 11/6/25 - Beat
MBX
Sec Filings
- 12/9/25 - Form EFFECT
- 11/25/25 - Form 4
- 11/14/25 - Form SCHEDULE
- MBX's page on the SEC website